

PB60121USW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Beswick et al.

Serial No.: 10568,399

Group Art Unit:

File Date:

Examiner:

For: 7-Azaindole Derivatives as COX2 Inhibitors

Director of the U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed; Ref. 20-44  
☐ Copies of the references were submitted in parent application \_\_\_\_\_ (37 CFR 1.98(d))  
☐ A copy of the International Search Report which issued on International Application No. \_\_\_\_\_ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action or after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. ☐ The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:  
(1) a final action under § 1.113 or  
(2) a notice of allowance under § 1.311, whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.


- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- ☒ Please charge any required fees to Deposit Account No.07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,

  
J. Scott Young  
Registration No. 45,582

Date: May 23 2006  
GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-8160  
Facsimile: (919) 483-7988

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>				<b>ATTORNEY DOCKET NO.</b> PB60121USW		<b>SERIAL NO.</b> 10/568,399	
				<b>APPLICANT:</b> Beswick et al			
				<b>FILING DATE:</b>		<b>GROUP</b>	

U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date if Appropriate
	1	2003/0013717	Jan. 16, 2003	Mangel et al.			
	2	3,149,109	Sept. 15, 1964	Neustaedter et al.			
	3	3,592,895	July 13, 1971	Hepworth et al.			
	4	5,474,995	Dec. 12, 1995	Ducharme et al.			
	5	5,760,068	June 2, 1998	Talley et al.			
	6	5,972,986	Oct. 26, 1999	Seibert et al.			
	7	6,020,343	Feb. 1, 2000	Belley et al.			
	8	6,153,619	Nov. 28, 2000	Wood et al.			
	9	6,306,866	Oct. 23, 2001	Wood et al.			
	10	6,313,072	Nov. 6, 2001	Scheiblich et al.			
	11	6,461,794	Sept. 17, 2002	Beswick et al.			
	12	6,498,166	Dec. 24, 2002	Campbell et al.			
	13	6,756,498	June 29, 2004	Fitzgerald et al.			
	14	6,759,413	July 6, 2004	Mangel et al.			
	15	6,780,869	Aug. 24, 2004	Green et al.			
	16	6,780,870 B2	Aug. 24, 2004	Carter et al.			
	17	6,803,463	Oct. 12, 2004	Mathews et al.			
	18	6,831,097	Dec. 14, 2004	Beswick et al.			
	19	6,861,249	Mar. 1, 2005	Kent			

Continue on page \_\_\_\_\_

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
	20	DE 19909541	Mar. 4, 1999	GERMANY			Abstract only
	21	JP 9241181	Sept. 16, 1997	Japan			X abstract only
	22	WO 96/07641	Mar. 14, 1996	WIPO			X abstract only
	23	WO 96/24585	Aug. 15, 1996	WIPO			
	24	WO 96/41625	Dec. 27, 1996	WIPO			
	25	WO 96/41645	Dec. 27, 1996	WIPO			
	26	WO 96/03484	Jan. 29, 1998	WIPO			
	27	WO 98/16227	Apr. 23, 1998	WIPO			
	28	WO 98/24782	June 11, 1998	WIPO			
	29	WO 99/01439	Jan. 14, 1999	WIPO			
	30	WO 02/18374	Mar. 27, 2002	WIPO			
	31	WO 02/96886	Dec. 5, 2002	WIPO			
	32	WO 03/14091	Feb. 20, 2003	WIPO			
	33	WO 03/77920	Sept. 25, 2003	WIPO			
	34	WO 04/18452	Mar. 4, 2003	WIPO			
	35	WO 04/24691	Mar. 25, 2004	WIPO			
	36	WO 04/48344	June 10, 2004	WIPO			

Continue on page \_\_\_\_\_

<b>OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)</b>	
Continue on page _____	
<b>EXAMINER</b>	<b>DATE CONSIDERED</b>

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

[illegible]